Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sugars as Energy Storage Molecules01:10

Sugars as Energy Storage Molecules

9.7K
Sugar (a simple carbohydrate) metabolism (chemical reactions) is a classic example of the many cellular processes that use and produce energy. Living things consume sugar as a major energy source because sugar molecules have considerable energy stored within their bonds. Consumed carbohydrates have their origins in photosynthesizing organisms like plants. During photosynthesis, plants use the energy of sunlight to convert carbon dioxide gas into sugar molecules, like glucose. Because this...
9.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

485
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
485
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.3K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

752
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
752
Implicit Memories01:24

Implicit Memories

396
Implicit memories, also known as non-declarative memories, are long-term memories that function outside of conscious awareness. These memories influence behavior and skills without explicit knowledge. This type of memory is evident in tasks like playing tennis, snowboarding, and texting. Implicit memory has three subsystems: procedural memory, conditioning, and priming. This type of memory is essential in various activities, from everyday tasks to specialized skills.
One key aspect of implicit...
396
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

490
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
490

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload.

Scientific reports·2025
Same author

Unfolding the Potential of Pyrrole- and Indole-Based Allylidene Hydrazine Carboximidamides as Antimicrobial Agents.

ACS infectious diseases·2025
Same author

Menaquinone biosynthesis inhibition: a review of advancements toward a new antibiotic mechanism.

RSC advances·2022
Same author

The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease.

International reviews of immunology·2021
Same author

Novel bisubstrate uridine-peptide analogues bearing a pyrophosphate bioisostere as inhibitors of human O-GlcNAc transferase.

Bioorganic chemistry·2021
Same author

Bisubstrate Ether-Linked Uridine-Peptide Conjugates as O-GlcNAc Transferase Inhibitors.

ChemMedChem·2020
Same journal

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same journal

Charting New Territory: Systematic Evaluation of the Drug Potential of <i>N</i>-Trifluoromethyl Amides, Ureas & Carbamates.

Journal of medicinal chemistry·2026
Same journal

Red-Light-Triggered <i>In Vitro</i> and <i>In Vivo</i> Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts.

Journal of medicinal chemistry·2026
Same journal

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same journal

HsClpP-Engaging Selective Mitochondrial Pan-PDK Degraders for Cancer Therapy.

Journal of medicinal chemistry·2026
Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Jan 4, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.0K

Sugar Kick Prevents Memory Impairment.

Santosh Rudrawar, Philip Ryan

    Journal of Medicinal Chemistry
    |November 1, 2019
    PubMed
    Summary
    This summary is machine-generated.

    Inhibiting O-GlcNAcase (OGA) with MK-8719 increases brain O-GlcNAc levels, reducing tau phosphorylation. This approach shows promise for treating neurodegenerative diseases like Alzheimer's by slowing progression and improving cognition.

    More Related Videos

    Barnes Maze Testing Strategies with Small and Large Rodent Models
    12:59

    Barnes Maze Testing Strategies with Small and Large Rodent Models

    Published on: February 26, 2014

    43.3K
    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
    09:45

    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

    Published on: March 22, 2016

    10.7K

    Related Experiment Videos

    Last Updated: Jan 4, 2026

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
    06:21

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

    Published on: April 7, 2023

    2.0K
    Barnes Maze Testing Strategies with Small and Large Rodent Models
    12:59

    Barnes Maze Testing Strategies with Small and Large Rodent Models

    Published on: February 26, 2014

    43.3K
    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
    09:45

    Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

    Published on: March 22, 2016

    10.7K

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Biochemistry

    Background:

    • Pathological tau hyperphosphorylation and aggregation into neurofibrillary tangles (NFTs) are hallmarks of neurodegenerative diseases like Alzheimer's disease (AD).
    • O-GlcNAcase (OGA) is the enzyme responsible for removing O-GlcNAc modifications from proteins, including tau.

    Purpose of the Study:

    • To investigate the therapeutic potential of inhibiting O-GlcNAcase (OGA) for neurodegenerative diseases characterized by tau pathology.
    • To evaluate the effects of a novel OGA inhibitor, MK-8719, on tau phosphorylation and cognitive function.

    Main Methods:

    • Utilized MK-8719, a selective and potent small molecule inhibitor of human O-GlcNAcase (hOGA).
    • Assessed the impact of pharmacological OGA inhibition on global brain O-GlcNAc levels and tau phosphorylation.
    • Evaluated the effects of OGA inhibition on neurodegeneration and cognitive function in models of AD and tauopathies.

    Main Results:

    • Pharmacological inhibition of OGA led to increased global O-GlcNAc levels in the brain.
    • OGA inhibition effectively reduced tau phosphorylation.
    • The OGA inhibitor demonstrated a capacity to slow neurodegeneration and improve cognitive function in relevant disease models.

    Conclusions:

    • Inhibition of O-GlcNAcase (OGA) represents a promising therapeutic strategy for Alzheimer's disease and related tauopathies.
    • MK-8719 and similar OGA inhibitors may offer a novel approach to treating age-related memory impairment and neurodegeneration.